Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metabolically armed BCMA CAR-T cells
- Development stage
- Phase 1
- Lead developer
- Leman Biotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
Metabolically armed BCMA CAR-T cells (specifically the Meta10-BCMA candidate) are autologous T cells engineered to express a chimeric antigen receptor (CAR) targeting B-cell maturation antigen (BCMA), further modified to enhance their metabolic fitness. Developed by The First Affiliated Hospital of USTC (Anhui Provincial Hospital), the Meta10 platform involves engineering CAR-T cells to co-express metabolic modulators—such as IL-10—that promote oxidative phosphorylation and mitochondrial biogenesis. This metabolic "arming" is designed to prevent T-cell exhaustion and improve persistence within the immunosuppressive microenvironment of plasma cell neoplasms. The therapy is currently being evaluated in Phase 1 clinical trials for the treatment of relapsed or refractory multiple myeloma, plasma cell leukemia, and AL amyloidosis.
- Brand names
- Metabolically Armed BCMA CAR-T cells
- Other names
- metabolically armed BCMA CAR-TMeta10-BCMAMeta-10-BCMAMeta 10-BCMA
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on metabolically armed BCMA CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metabolically armed BCMA CAR-T cells.